srch

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug ...

Find the latest financial analysis of BerGenBio ASA and other vital information on Euronext Live. ... Investment cash flows, -2,557, -346, -234, 2,279 ...

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of ... Contact: ir@bergenbio.com Rune Skeie, CFO, BerGenBio ASA ...

BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers.

Find the latest SEC Filings data for BerGenBio ASA (BRRGF) at Nasdaq.com. Skip to main ... Investor Relations ... This information can be used by …

Subscribe to our newsletter. Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events.

BerGenBio regularly presents clinical and pre-clinical data at leading scientific congresses and shares company updates at investor relation conferences. Below are presentations given by the company’s senior management and clinical collaborators. Corporate Presentations 2021 2020 2019 2018 2017 Scientific Presentations 2021 2020 2019 2018 2017

15 feb. Vis BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021. 7 feb. Vis BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST.

Bergen, Norway, 4 August 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage ... Investors/Financial Reports section. ... ir@bergenbio.com

Mar 17, 2022 · Subscribe to our newsletter. Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events.

May 19, 2021 · 25 February 2021. Annual report 2020. 19 March 2021. Annual General Meeting. 19 May 2021. Quarterly Report – Q1 2021. 17 August 2021. Half-year report 2021. 16 November 2021.

16.02.2022 · BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for the fourth ...

27.01.2022 · Investor Relations PR Newswire BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients

Mar 11, 2022 · BerGenBio has not paid any dividends for the year ended 31 December 2020 or any previous year. The Company is focusing on the development of novel pharmaceutical products and does not anticipate paying any cash dividend until sustainable profitability is achieved.

17.03.2022 · Investors. Yearly Reports Annual Report 2020. BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers. Our …

BerGenBio ASA: Annual General Meeting Bergen, Norway, 14 May 2018 - The Annual ... 1 June, Sachs Immuno-Oncology BD&L and Investment Forum (Chicago, IL)*

Bergenbio - Investor Relations & Communications Manager. Finn drømmejobben gjennom KarriereStart.no - startsiden for jobb og karriere.

Mar 17, 2022 · Investors. Yearly Reports Annual Report 2020. BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases ...